Mobile Diagnostic appoints new marketing, operations director

TriMed Staff | | Health Imaging | Artificial Intelligence
Mobile Diagnostic Centers has appointed Patrick McNamara as director of marketing and operations.

McNamara will lead the Mobile Diagnostic Centers' team in launching, managing and growing the company's mobile imaging routes. McNamara has more than eight years experience managing and developing mobile imaging routes. He will oversee all the hiring and training of imaging personnel, according to the Las Vegas-based company.

Additionally, McNamara will be responsible for developing and executing the marketing plan, according to Michael Blumenthal, president and CEO of Mobile Imaging Development.

McNamara's previous mobile imaging experience includes the formation of a mobile PET/CT route that was launched just after the introduction of the Deficit Reduction Act of 2005.

TriMed Staff

Related Content

AI beats standard regression models at predicting lung cancer risk
AI reduces CT lung cancer screening workload by nearly 80%
How AI and CCTA help heart teams plan ahead before PCI
5 steps for evaluating radiology AI applications
Adaptable AI system detects subtle changes in imaging, has potential across multiple clinical settings
New algorithm models radiologists' eye movements to interpret chest X-rays

Around the web

Cardiovascular Business
ASE updates recommendations for assessing right heart function in patients with pulmonary hypertension

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.